Clinical Trials
2 trialsNCT06589804 2026-05-22
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT07441681 2026-05-04
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
NRG Oncology
Phase 3 Not yet recruiting